Kevin Sayer has been the CEO of DexCom, Inc. since 2015, where he has played a crucial role in transforming diabetes management through innovative technology. Holding a Master's degree in Accounting and Information Systems from Brigham Young University, Kevin has...

Kevin Sayer has been the CEO of DexCom, Inc. since 2015, where he has played a crucial role in transforming diabetes management through innovative technology. Holding a Master's degree in Accounting and Information Systems from Brigham Young University, Kevin has a strong background in finance and healthcare. Prior to DexCom, he served as the Chief Financial Officer of Biosensors International Group, a company focused on medical devices, enhancing his expertise in this field. Sayer is a Certified Public Accountant, which underlines his financial acumen. In 2023, his total compensation was approximately $15.7 million, reflecting both his leadership and the company's performance, where his salary was $1.1 million, a bonus of around $2 million, and vested stock valued at a whopping $13.5 million. Beyond numbers, what stands out is his steady journey at DexCom since 2007, starting from a board member to becoming the CEO, indicating a deep-rooted commitment to the company and its mission. Sayer’s involvement in shaping the future of diabetes care has proven pivotal, especially through the company’s performance metrics that focus on revenue and operational goals, which directly tie to patient care enhancements.